Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Yatin Suneja will join the firm in November as a Managing Director, continuing the firm’s planned expansion of the Healthcare Research team. Mr. Suneja will focus on the coverage of Biotechnology companies in close collaboration with our growing therapeutics team.
The U.S. economy remains on solid footing, explain Portfolio Manager Adam Bloch and Brian Smedley, head of the Macroeconomic and Investment Research Group, but trade war risk, a flattening yield curve, and other factors signal challenges ahead that warrant portfolio changes.
While the U.S. economy remains on solid footing, trade war risk, a flattening yield curve and other factors signal recession ahead and warrant portfolio changes.
Ideas for portfolio positioning amid tight credit spreads and a flattening yield curve.
Lower term premiums and a flat yield curve are transitory effects of fiscal stimulus.
Geopolitical tensions could give rise to substantial supply disruptions.
Government borrowing and the Fed balance sheet runoff are flooding T-bill supply.
The markets will be tested by the reaction of passive investors when Fed tightening leads to a credit downturn.
Guggenheim Securities announced today that Whitney Ijem has joined the firm as a Director in a planned expansion of the Healthcare Research team. Ms. Ijem is focusing on the coverage of Biotech companies, working closely with the firm’s growing therapeutics team.
Scott Minerd, Chairman of Investments and Global CIO, explains on Bloomberg TV why trade wars will hurt U.S. consumers as much as the countries targeted by the Trump administration’s tariffs.
You are now leaving this website.Guggenheim assumes no responsibility of the content or its accuracy.
Your browser does not support iframes.
2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.